Radiation dosimetry results for zevalin radioimmunotherapy of rituximab-refractory non-hodgkin lymphoma

200285 citationsJournal Articlebronze Open Access

Authors

Gregory A. Wiseman · Mayo Clinic

Bryan R. Leigh · Sparks

William D. Erwin · Northwestern University

Dominick Lamonica · Sparks

Ellen Kornmehl · Harvard University

Stewart Spies · Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Daniel Silverman ·

Abstract

Zevalin treatment of rituximab-refractory follicular NHL patients at 0.4 mCi/kg resulted in acceptable estimates of absorbed radiation dose to organs, similar to those observed in other Zevalin-treated populations.

Topics & Keywords

Lymphoma Diagnosis and Treatment Radiopharmaceutical Chemistry and Applications Cancer Immunotherapy and Biomarkers

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer

Volume 94, Issue S4, pp. 1349-1357

DOI: 10.1002/cncr.10305

Field-Weighted Citation Impact: 5.83